Acknowledged as “Exceeding Customer Expectations” across 14 categories
East Rutherford, NJ – 28 March, 2017 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it had been successful in 14 categories at the annual CMO (Contract Manufacturing Organization) Leadership Awards, which were announced at a ceremony in New York, on March 22.
Overall, Cambrex received 24 awards, across all categories including capabilities, compatibility, development, expertise, quality and reliability.
“Being recognized for the hard work undertaken by our scientists and management by industry peers is testament to the dedication, expertise and attention to detail that our team employs on each and every project we undertake,” commented Simon Edwards, Vice President, Global Sales and Business Development. He added, “We would like to thank the organizers of the event in continuing to highlight the key role CMOs play within the industry, and we are honored to be recognized as one of the leading companies supporting the wider pharmaceutical community.”
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Life Science Leader magazine and Industry Standard Research.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Director, Marketing and Communications
Tel: +44 7803 443 155